Reneo Pharmaceuticals (RPHM)
(Delayed Data from NSDQ)
$1.75 USD
+0.09 (5.42%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPHM 1.75 +0.09(5.42%)
Will RPHM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RPHM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPHM
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
RPHM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RPHM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Reneo Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying
Mitchell Kapoor’s Hold Rating on Reneo Pharmaceuticals Amid OnKure Merger and Oncology Pipeline Potential
RPHM Alert: Monsey Firm of Wohl & Fruchter Investigating Proposed Merger of Reneo Pharmaceuticals With OnKure
Reneo Pharmaceuticals Announces Merger and Strategic PIPE Investment